News | September 11, 2024
Evonik starts operation of new spray drying facility for pharmaceutical oral excipients
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The recent inspection covered both cGMP and PAI processes
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
This project is supported by the Irish Government through IDA Ireland
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Subscribe To Our Newsletter & Stay Updated
